Healthy Skepticism Library item: 585

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: Journal Article

Vitry A, Mansfield P.
Promotion of Coversyl by Servier.
Lancet 1996 May 18; 347:(9012):1411

Keywords:
*letter to the editor United Kingdom Australia Servier quality of information regulation of promotion Australian Pharmaceutical Manufacturers Association ABPI Association of the British Pharmaceutical Industry Code of Practice (UK) Coversyl perindopril REGULATION, CODES, GUIDELINES: FEEDBACK TO COMPANIES REGULATION, CODES, GUIDELINES: INDUSTRY SELF-REGULATION

Notes:

The Medical Lobby for Appropriate Marketing rejects Servier’s evidence that Coversyl produces any clinically important vascular remodeling. Servier’s promotion of Coversyl was in breach of the Association of the British Pharmaceutical Industry’s Code of Practice three times in 1995 and 1996. The author’s have complained about Servier to the Australian Pharmaceutical Manufacturers Association. Three months later, Servier which is not a member of the APMA, has not yet agreed to let the complaint be heard. It seems that industry self-regulation does not prevent repeat offences.